Navigation Links
U of Alberta researcher discovers potential cancer therapy target
Date:2/14/2011

One of the most important genes in the human genome is called p53 and its function is to suppress tumours, according to Roger Leng, a researcher in the Faculty of Medicine & Dentistry. Leng has discovered the mechanism by which p53 is inactivated in cancerous cells, allowing tumours to grow.

"Successful completion of the proposed experiments could lead to novel anti-cancer therapies that could potentially improve the prognosis for cancer patients and reduce the public health burden from cancer," said Leng.

It has long been known by scientists that another protein, MDM2, lowers p53 in the body, but in cancerous cells p53 is inactivated in more than 50 per cent of all human tumours. MDM2 does not have the ability to functionally silence the tumour suppressing protein on its own, leaving scientists wondering what molecule in the body is helping MDM2 to nearly eliminate p53 in cancerous cells.

Leng's lab has answered that question and the culprit is called UBE4B. Leng made the discovery because he found that UBE4B binds with both p53 and MDM2. From there his lab was able to discover the relationship between the proteins.

Paired with MDM2, also known as HDM2 in humans, the two proteins completely degrade p53 in a laboratory model. This is a process known as poly-ubiquitination, which means a specific protein completely disappears in a cell.

They also did experiments on cancerous human brain tissue and found the same results.

"They have the same function," said Leng. "The idea now is you can target UBE4B and MDM2 won't function."

This discovery landed Leng in the pages of one of the highest-impact scientific journals, Nature Medicine. His work was published online on Sunday, Feb. 13.

Now, the Alberta Heritage Foundation for Medical Research Scholar and Canadian Institutes of Health Research funded scientist wants to further understand the mechanisms by which UBE4B functions.

"We want to understand how it regulates MDM2," said Leng. "We also want to see, if you get DNA damage, what happens in UBE4B and p53."

All of which could provide answers which eventually lead to a pharmacological target for cancer therapy.


'/>"/>

Contact: Quinn Phillips
quinn.phillips@ualberta.ca
780-399-7505
University of Alberta Faculty of Medicine & Dentistry
Source:Eurekalert

Related biology news :

1. U of Alberta researchers discover important mechanism in fighting infection
2. U Alberta-led team studies T cell activation with nanoparticles
3. U Alberta find could shield humans from influenza virus
4. U of Alberta researchers find mechanism that could prevent or treat deadly peroxisome diseases
5. U Alberta researcher in same group as Darwin and Hawking
6. New dinosaur species possible in Northwestern Alberta
7. A new dinosaur species, Pachyrhinosaur lakustai, unveiled from Pipestone Creek, Alberta, Canada
8. Boston University School of Medicine researchers receive NIMH brain awards
9. Just in time for Valentines Day: UNC researchers identify a gene critical for heart function
10. Johns Hopkins researchers capture jumping genes
11. The brain knows what the nose smells, but how? Stanford researchers trace the answer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading ... (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. ... tables for its annual event, which will run from 3:00 p.m. - 8:30 ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... ... , ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery ... has been selected to present at the Cavendish Global Health Impact Forum taking place ... purpose of the Forum is to help family offices and foundations develop and implement ...
(Date:2/9/2016)... Feb. 9, 2016  Regenicin, Inc. (OTC Bulletin ... in the development and commercialization of regenerative cell ... and organs, recently reported the Company,s operating results ... of 2016. Lonza America , Inc. ... fiscal year in the process of consummating an ...
Breaking Biology Technology: